Related Experiment Video

Updated: Aug 25, 2026

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
07:38

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

Participation of the matrix metalloproteinase inhibitor in Thy-1 nephritis

Osamu Mitani1, Masahiro Katoh, Hidekazu Shigematsu

  • 1Department of Pathology, Shinshu University School of Medicine, Matsumoto, Japan. osamu_mitani@maruishi-pharm.co.jp

Pathology International
|March 19, 2004
PubMed

Insights

The matrix metalloproteinase (MMP) inhibitor SI-27 reduced early cell and matrix increases in Thy-1 glomerulonephritis but did not prevent recovery of glomerular structures.

Area of Science:

  • Nephrology
  • Immunology
  • Biochemistry

Background:

  • Thy-1 glomerulonephritis is an autoimmune kidney disease characterized by inflammation and extracellular matrix deposition.
  • Matrix metalloproteinases (MMPs) are implicated in the pathogenesis of kidney diseases, but their specific role in Thy-1 nephritis requires further elucidation.

Purpose of the Study:

  • To investigate the therapeutic effect of the synthetic MMP inhibitor SI-27 on Thy-1 glomerulonephritis in a rat model.
  • To analyze the impact of SI-27 on glomerular histology, extracellular matrix components, and MMP activity during the course of the disease.

Main Methods:

  • Five groups of Wistar rats were studied: healthy, treated healthy, nephritic, and nephritic groups treated with SI-27 before or after disease induction.
  • Renal histology, extracellular matrix (ECM) constituents (type I and IV collagen), and MMP activity (MMP-2 and MMP-9) were assessed at multiple time points (days 7, 14, 26, and 42) post-induction.
  • SI-27 treatment was administered either 2 days before or 2 days after anti-Thy-1.1 antibody injection.

Main Results:

  • SI-27 treatment significantly reduced glomerular cells, including alpha-smooth muscle actin (alpha-SMA) positive mesangial cells, and suppressed type IV collagen expression at day 7.
  • Type I collagen levels were also decreased by SI-27 at day 42.
  • MMP-9 expression was transiently induced by SI-27 in treated groups at day 7 but absent in untreated nephritic rats; MMP-2 activity was consistently observed in nephritic rats.

Conclusions:

  • MMP inhibition by SI-27 can mitigate initial cellular and matrix proliferation in Thy-1 glomerulonephritis.
  • Despite early intervention, SI-27 does not impede the eventual recovery of normal glomerular capillary structures in this model.
  • These findings highlight the complex role of MMPs in the development and resolution of Thy-1 nephritis.

Related Concept Videos

Role of Matrix Metalloproteases in Degradation of ECM01:23

Role of Matrix Metalloproteases in Degradation of ECM

Matrix metalloproteases (MMPs) are enzymes involved in the hydrolysis of proteins and glycoproteins of the extracellular matrix. MMPs are essential for the migration and proliferation of cells through the dense matrix network, throughout embryonic development, and throughout morphogenesis. The first MMP activity discovered was a collagenase in a tadpole's tail undergoing metamorphosis. The active collagen deposition and modifications lead to the morphogenesis of tadpoles into the adult body.
A...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...